A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RX108 in Patients with Advanced or Metastatic Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2016
At a glance
- Drugs RX 108 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Suzhou NeuPharma
- 10 Jun 2015 New trial record
- 08 Jun 2015 Dosing of this Phase I study has been commenced, as reported in Suzhou NeuPharma media release.